Heat Biologics Company Profile (NASDAQ:HTBX)

About Heat Biologics (NASDAQ:HTBX)

Heat Biologics logoHeat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HTBX
  • CUSIP: N/A
  • Web: www.heatbio.com
Capitalization:
  • Market Cap: $23.52 million
  • Outstanding Shares: 33,526,000
Average Prices:
  • 50 Day Moving Avg: $0.75
  • 200 Day Moving Avg: $0.98
  • 52 Week Range: $0.52 - $3.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.92
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $341,643.00
  • Price / Sales: 68.83
  • Book Value: $0.34 per share
  • Price / Book: 2.09
Profitability:
  • EBIDTA: ($13,000,000.00)
  • Return on Equity: -516.63%
  • Return on Assets: -147.96%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.71%
  • Quick Ratio: 2.71%
Misc:
  • Average Volume: 778,816 shs.
  • Beta: 0.93
  • Short Ratio: 1.99
 

Frequently Asked Questions for Heat Biologics (NASDAQ:HTBX)

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) announced its quarterly earnings results on Friday, March, 31st. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.05. The firm earned $0.12 million during the quarter, compared to the consensus estimate of $0.13 million. View Heat Biologics' Earnings History.

Where is Heat Biologics' stock going? Where will Heat Biologics' stock price be in 2017?

2 brokers have issued 12 month price targets for Heat Biologics' stock. Their predictions range from $2.00 to $8.00. On average, they expect Heat Biologics' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Heat Biologics.

Who are some of Heat Biologics' key competitors?

Who owns Heat Biologics stock?

Heat Biologics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (7.29%), Vanguard Group Inc. (1.76%) and KCG Holdings Inc. (0.52%). View Institutional Ownership Trends for Heat Biologics.

Who bought Heat Biologics stock? Who is buying Heat Biologics stock?

Heat Biologics' stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, Vanguard Group Inc. and KCG Holdings Inc.. View Insider Buying and Selling for Heat Biologics.

How do I buy Heat Biologics stock?

Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Heat Biologics stock cost?

One share of Heat Biologics stock can currently be purchased for approximately $0.70.

Analyst Ratings

Consensus Ratings for Heat Biologics (NASDAQ:HTBX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (612.86% upside)

Analysts' Ratings History for Heat Biologics (NASDAQ:HTBX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2017Noble FinancialReiterated RatingBuyHighView Rating Details
12/8/2016Roth CapitalSet Price TargetBuy$2.00N/AView Rating Details
4/9/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
2/21/2016HC WainwrightReiterated RatingBuy$13.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Heat Biologics (NASDAQ:HTBX)
Earnings by Quarter for Heat Biologics (NASDAQ:HTBX)
Earnings History by Quarter for Heat Biologics (NASDAQ:HTBX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/31/2017Q4 2016($0.07)($0.12)$0.13 million$0.12 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.15)($0.08)$0.22 millionViewN/AView Earnings Details
8/15/2016Q2($0.27)($0.17)ViewN/AView Earnings Details
5/11/2016Q1($0.56)($0.50)ViewN/AView Earnings Details
2/18/2016Q4($0.64)($0.78)ViewN/AView Earnings Details
10/30/2015Q3($0.61)($0.62)ViewN/AView Earnings Details
8/13/2015Q2($0.47)($0.56)ViewN/AView Earnings Details
5/14/2015Q1($0.49)($0.57)ViewN/AView Earnings Details
4/16/2015($0.49)($0.56)ViewN/AView Earnings Details
3/27/2015Q4 2014($0.44)($0.56)ViewN/AView Earnings Details
11/14/2014Q314($0.35)($0.46)ViewN/AView Earnings Details
8/14/2014Q214($0.38)($0.44)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.38)($0.36)ViewN/AView Earnings Details
4/1/2014($0.30)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heat Biologics (NASDAQ:HTBX)
Current Year EPS Consensus Estimate: $-0.6300 EPS
Next Year EPS Consensus Estimate: $-0.7600 EPS

Dividends

Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Heat Biologics (NASDAQ:HTBX)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 1.78%
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)
Institutional Ownership by Quarter for Heat Biologics (NASDAQ:HTBX)
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00View SEC Filing  
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Heat Biologics (NASDAQ:HTBX)
Latest Headlines for Heat Biologics (NASDAQ:HTBX)
Source:
DateHeadline
americanbankingnews.com logoHeat Biologics Inc (HTBX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 27 at 12:58 AM
americanbankingnews.com logoNoble Financial Reaffirms "Buy" Rating for Heat Biologics Inc (HTBX)
www.americanbankingnews.com - May 14 at 8:44 AM
reuters.com logoBRIEF-Heat Biologics says net loss for Q1 of 2017 was $3.2 million
www.reuters.com - May 11 at 11:22 PM
streetinsider.com logoForm 8-K HEAT BIOLOGICS, INC. For: May 11
www.streetinsider.com - May 11 at 6:21 PM
finance.yahoo.com logoHeat Biologics Provides Business and Clinical Update for the First Quarter of 2017
finance.yahoo.com - May 11 at 6:21 PM
finance.yahoo.com logoHeat Bio pivots, will focus on combination therapies for cancer
finance.yahoo.com - May 11 at 6:21 PM
americanbankingnews.com logoHeat Biologics Inc (HTBX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 11:26 PM
americanbankingnews.com logoZacks Investment Research Downgrades Heat Biologics Inc (HTBX) to Hold
www.americanbankingnews.com - May 5 at 11:16 PM
americanbankingnews.com logoPositive News Coverage Somewhat Likely to Affect Heat Biologics (HTBX) Stock Price
www.americanbankingnews.com - May 4 at 11:40 AM
finance.yahoo.com logoHeat Bio completes acquisition of Texas company
finance.yahoo.com - May 2 at 4:14 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Likely to Impact Heat Biologics (HTBX) Share Price
www.americanbankingnews.com - May 1 at 7:32 PM
finance.yahoo.com logoHeat Biologics Announces Completion of Acquisition of Pelican Therapeutics - Yahoo Finance
finance.yahoo.com - May 1 at 1:29 PM
finance.yahoo.com logoHeat Biologics Announces Completion of Acquisition of Pelican Therapeutics
finance.yahoo.com - May 1 at 1:29 PM
americanbankingnews.com logoHeat Biologics (HTBX) Receives Daily Media Sentiment Rating of 0.31
www.americanbankingnews.com - April 28 at 12:10 AM
finance.yahoo.com logoHeat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
finance.yahoo.com - April 26 at 7:34 PM
americanbankingnews.com logoHeat Biologics (HTBX) Given Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 24 at 10:52 AM
americanbankingnews.com logoHeat Biologics (HTBX) Given Media Sentiment Rating of 0.37
www.americanbankingnews.com - April 21 at 4:14 PM
americanbankingnews.com logoHeat Biologics (HTBX) Receiving Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 18 at 6:49 PM
americanbankingnews.com logoHeat Biologics Inc (HTBX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:25 PM
americanbankingnews.com logoHeat Biologics Inc (HTBX) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 7 at 10:07 PM
finance.yahoo.com logoHeat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 7 at 10:18 AM
finance.yahoo.com logoOncoSec collaboration data 'promising' for embattled Heat Bio
finance.yahoo.com - April 7 at 10:18 AM
finance.yahoo.com logoHeat Biologics Reports Fiscal Year 2016 Financial Results
finance.yahoo.com - March 31 at 5:48 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - March 31 at 5:48 PM
finance.yahoo.com logoHeat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock
finance.yahoo.com - March 28 at 5:24 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - March 24 at 9:53 AM
americanbankingnews.com logoHeat Biologics Inc (HTBX) Receives Buy Rating from Noble Financial
www.americanbankingnews.com - March 23 at 7:37 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 23 at 6:20 PM
us.rd.yahoo.com logoHeat Biologics Prices Offering of 5,000,000 Shares of Common Stock
us.rd.yahoo.com - March 23 at 6:20 PM
finance.yahoo.com logo2 Health Care Stocks Crushed on Thursday
finance.yahoo.com - March 23 at 6:20 PM
streetinsider.com logoHeat Biologics (HTBX) Plans Offering of Common Stock
www.streetinsider.com - March 22 at 5:56 PM
finance.yahoo.com logoHeat Biologics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 22 at 5:56 PM
investopedia.com logoHeat Biologics Reports Positive NSCLC Drug Results (HTBX)
www.investopedia.com - March 21 at 5:46 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Posts Good Results
www.investopedia.com - March 21 at 5:46 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Posts Good Results
www.investopedia.com - March 21 at 5:46 PM
americanbankingnews.com logoZacks: Heat Biologics Inc (HTBX) Given $4.00 Consensus Target Price by Analysts
www.americanbankingnews.com - March 21 at 11:52 AM
us.rd.yahoo.com logoHeat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
us.rd.yahoo.com - March 21 at 9:12 AM
finance.yahoo.com logoHeat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City
finance.yahoo.com - March 20 at 7:02 PM
bizjournals.com logoHeat Biologics faces threat of delisting – again
www.bizjournals.com - March 16 at 10:38 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa
us.rd.yahoo.com - March 16 at 4:25 PM
us.rd.yahoo.com logoFlorida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
us.rd.yahoo.com - March 16 at 4:25 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Combo Succeeds
www.investopedia.com - March 13 at 5:39 PM
streetinsider.com logoHeat Biologics (HTBX) Says it Met Efficacy Endpoint in Phase 1b Lung Cancer Trial
www.streetinsider.com - March 13 at 11:02 AM
us.rd.yahoo.com logoHeat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
us.rd.yahoo.com - March 13 at 11:02 AM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 11:02 AM
finance.yahoo.com logoHeat Biologics to Present at 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 3:50 PM
finance.yahoo.com logoBlog Coverage Heat Biologics Acquires Controlling Stake in Immuno-Oncology Company Pelican Therapeutics
finance.yahoo.com - March 9 at 3:50 PM
bizjournals.com logoAustin cancer-fighting startup to rejoin public company it spun out from in 2012
www.bizjournals.com - March 9 at 3:50 PM
us.rd.yahoo.com logoHeat Biologics Announces Agreement to Acquire Pelican Therapeutics
us.rd.yahoo.com - March 8 at 6:34 PM
us.rd.yahoo.com logo7:02 am Heat Biologics to acquire 80% of Pelican Therapeutics for $500k in cash & about 1.32 mln shares of HTBX common stock
us.rd.yahoo.com - March 8 at 6:34 PM

Social

Chart

Heat Biologics (HTBX) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff